Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1995 Feb 15;306(Pt 1):77–85. doi: 10.1042/bj3060077

Interaction of non-conjugated olefinic substrate analogues with dopamine beta-monooxygenase: catalysis and mechanism-based inhibition.

S R Sirimanne 1, S W May 1
PMCID: PMC1136484  PMID: 7864832

Abstract

The reaction of dopamine beta-monooxygenase (DBM; EC 1.14.17.1) with the prototypical non-conjugated olefinic substrate, 2-(1-cyclohexenyl)ethylamine (CyHEA) [see Sirimanne and May (1988) J. Am. Chem. Soc. 110, 7560-7561], was characterized. CyHEA undergoes facile DBM-catalysed allylic hydroxylation to form (R)-2-amino-1-(1-cyclohexenyl)ethanol (CyHEA-OH) without detectable epoxidation or allylic hydroxylation to form (R)-2-amino-1-(1-cyclohexenyl)ethanol (CyHEA-OH) without detectable epoxidation or allylic rearrangement, and with stereochemistry consistent with that of DBM-catalysed benzylic hydroxylation and sulphoxidation. The kcat. of 90 s-1 for CyHEA oxygenation is about 75% of the kcat. for tyramine, the substrate commonly used in assays of DBM activity. DBM-catalysed oxygenation of CyHEA also results in mechanism-based inactivation of DBM, with the inactivation reaction yielding kinact. = 0.3 min-1 at pH 5.0 and 37 degrees C, and a partition ratio of 16,000. Although both CyHEA turnover and inactivation exhibit normal kinetics, CyHEA processing also results in gradual depletion of copper from DBM; however, mechanism-based irreversible DBM inactivation occurs independent of this copper depletion when sufficient copper is present in the assay solution. A likely mechanism for turnover-dependent DBM inactivation by CyHEA involves initial abstraction of an allylic hydrogen to form a resonance-stabilized allylic radical, which can then either partition to product or undergo attack by an active-site residue. Acyclic, non-conjugated olefinic analogues exhibit diminished substrate activity toward DBM. Thus, kcat. for oxygenation of cis-2-hexenylamine, which also produces only allylic alcohol product, is only 14% of that for CyHEA. Similarly, kinact./KI for turnover-dependent inactivation by the acyclic olefin 2-aminomethyl-1-pentene is more than an order of magnitude smaller than that for benzylic olefins. Our results establish that DBM catalyses allylic oxygenation of a number of non-conjugated olefinic substrate analogues with neither epoxidation nor allylic rearrangement occurring. The absence of epoxide products from non-conjugated olefinic substrates implies an inability of the activated copper-oxygen species of DBM to effect radical cation formation from a non-conjugated olefinic moiety. The striking contrast between DBM and cytochrome P-450, which carries out both epoxidation and allylic oxidation with non-conjugated olefinic substrates, is probably a reflection of the differences in redox potential of the activated oxygen species operative for these two enzymes.

Full text

PDF
77

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aberg H. E., Hansson H. E., Wetterberg L., Ross S. B., Frödén O. Dopamine-beta-hydroxylase in human lymph. Life Sci. 1974 Jan 1;14(1):65–71. doi: 10.1016/0024-3205(74)90246-x. [DOI] [PubMed] [Google Scholar]
  2. Baldoni J. M., Villafranca J. J. Dopamine beta-hydroxylase. Inactivation by a suicide substrate. J Biol Chem. 1980 Oct 10;255(19):8987–8990. [PubMed] [Google Scholar]
  3. Bargar T. M., Broersma R. J., Creemer L. C., McCarthy J. R., Hornsperger J. M., Palfreyman M. G., Wagner J., Jung M. J. Unsaturated heterocyclic amines as potent time-dependent inhibitors of dopamine beta-hydroxylase. J Med Chem. 1986 Mar;29(3):315–317. doi: 10.1021/jm00153a002. [DOI] [PubMed] [Google Scholar]
  4. Battersby A. R., Sheldrake P. W., Staunton J., Williams D. C. Studies of enzyme-mediated reactions. Part VII. Stereospecific syntheses of tritium-labelled (2R)- and (2S)-dopamines: stereochemical course of hydroxylation of dopamine by dopamine beta-hydroxylase (E.C. 1.14.17.1). J Chem Soc Perkin 1. 1976;(10):1056–1062. doi: 10.1039/p19760001056. [DOI] [PubMed] [Google Scholar]
  5. Cleland W. W. The statistical analysis of enzyme kinetic data. Adv Enzymol Relat Areas Mol Biol. 1967;29:1–32. doi: 10.1002/9780470122747.ch1. [DOI] [PubMed] [Google Scholar]
  6. Colombo G., Papadopoulos N. J., Ash D. E., Villafranca J. J. Characterization of highly purified dopamine beta-hydroxylase. Arch Biochem Biophys. 1987 Jan;252(1):71–80. doi: 10.1016/0003-9861(87)90009-9. [DOI] [PubMed] [Google Scholar]
  7. Colombo G., Rajashekhar B., Giedroc D. P., Villafranca J. J. Alternate substrates of dopamine beta-hydroxylase. I. Kinetic investigations of benzyl cyanides as substrates and inhibitors. J Biol Chem. 1984 Feb 10;259(3):1593–1600. [PubMed] [Google Scholar]
  8. Colombo G., Villafranca J. J. An acetylenic mechanism-based inhibitor of dopamine beta-hydroxylase. J Biol Chem. 1984 Dec 25;259(24):15017–15020. [PubMed] [Google Scholar]
  9. Fitzpatrick P. F., Flory D. R., Jr, Villafranca J. J. 3-Phenylpropenes as mechanism-based inhibitors of dopamine beta-hydroxylase: evidence for a radical mechanism. Biochemistry. 1985 Apr 23;24(9):2108–2114. doi: 10.1021/bi00330a003. [DOI] [PubMed] [Google Scholar]
  10. Fitzpatrick P. F., Villafranca J. J. The mechanism of inactivation of dopamine beta-hydroxylase by hydrazines. J Biol Chem. 1986 Apr 5;261(10):4510–4518. [PubMed] [Google Scholar]
  11. Goldstein D. J., Cubeddu L. X. Dopamine-beta-hydroxylase activity in human cerebrospinal fluid. J Neurochem. 1976 Jan;26(1):193–195. [PubMed] [Google Scholar]
  12. Goodhart P. J., DeWolf W. E., Jr, Kruse L. I. Mechanism-based inactivation of dopamine beta-hydroxylase by p-cresol and related alkylphenols. Biochemistry. 1987 May 5;26(9):2576–2583. doi: 10.1021/bi00383a025. [DOI] [PubMed] [Google Scholar]
  13. Herman H. H., Wimalasena K., Fowler L. C., Beard C. A., May S. W. Demonstration of the ascorbate dependence of membrane-bound dopamine beta-monooxygenase in adrenal chromaffin granule ghosts. J Biol Chem. 1988 Jan 15;263(2):666–672. [PubMed] [Google Scholar]
  14. Husain P. A., Colbert J. E., Sirimanne S. R., VanDerveer D. G., Herman H. H., May S. W. N-succinimidyl methoxyphenylacetic acid ester, an amine-directed chiral derivatizing reagent suitable for enzymatic scale resolutions. Anal Biochem. 1989 Apr;178(1):177–183. doi: 10.1016/0003-2697(89)90376-x. [DOI] [PubMed] [Google Scholar]
  15. Kruse L. I., DeWolf W. E., Jr, Chambers P. A., Goodhart P. J. Design and kinetic characterization of multisubstrate inhibitors of dopamine beta-hydroxylase. Biochemistry. 1986 Nov 18;25(23):7271–7278. doi: 10.1021/bi00371a004. [DOI] [PubMed] [Google Scholar]
  16. LEVIN E. Y., LEVENBERG B., KAUFMAN S. The enzymatic conversion of 3,4-dihydroxyphenylethylamine to norepinephrine. J Biol Chem. 1960 Jul;235:2080–2086. [PubMed] [Google Scholar]
  17. Mangold J. B., Klinman J. P. Mechanism-based inactivation of dopamine beta-monooxygenase by beta-chlorophenethylamine. J Biol Chem. 1984 Jun 25;259(12):7772–7779. [PubMed] [Google Scholar]
  18. May S. W., Herman H. H., Roberts S. F., Ciccarello M. C. Ascorbate depletion as a consequence of product recycling during dopamine beta-monooxygenase catalyzed selenoxidation. Biochemistry. 1987 Mar 24;26(6):1626–1633. doi: 10.1021/bi00380a021. [DOI] [PubMed] [Google Scholar]
  19. May S. W., Mueller P. W., Padgette S. R., Herman H. H., Phillips R. S. Dopamine-B-hydroxylase: suicide inhibition by the novel olefinic substrate, 1-phenyl-1-aminomethylethene. Biochem Biophys Res Commun. 1983 Jan 14;110(1):161–168. doi: 10.1016/0006-291x(83)91274-3. [DOI] [PubMed] [Google Scholar]
  20. May S. W., Phillips R. S., Mueller P. W., Herman H. H. Dopamine beta-hydroxylase. Demonstration of enzymatic ketonization of the product enantiomer S-octopamine. J Biol Chem. 1981 Mar 10;256(5):2258–2261. [PubMed] [Google Scholar]
  21. Padgette S. R., Wimalasena K., Herman H. H., Sirimanne S. R., May S. W. Olefin oxygenation and N-dealkylation by dopamine beta-monooxygenase: catalysis and mechanism-based inhibition. Biochemistry. 1985 Oct 8;24(21):5826–5839. doi: 10.1021/bi00342a021. [DOI] [PubMed] [Google Scholar]
  22. Ross S. T., Kruse L. I., Ohlstein E. H., Erickson R. W., Ezekiel M., Flaim K. E., Sawyer J. L., Berkowitz B. A. Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones. J Med Chem. 1987 Aug;30(8):1309–1313. doi: 10.1021/jm00391a008. [DOI] [PubMed] [Google Scholar]
  23. Sirimanne S. R., Herman H. H., May S. W. Interaction of dopamine beta-mono-oxygenase with substituted imidazoles and pyrazoles. Catalysis and inhibition. Biochem J. 1987 Feb 15;242(1):227–233. doi: 10.1042/bj2420227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Weinshilboum R., Axelrod J. Serum dopamine-beta-hydroxylase activity. Circ Res. 1971 Mar;28(3):307–315. doi: 10.1161/01.res.28.3.307. [DOI] [PubMed] [Google Scholar]
  25. Winkler H., Hörtnagl H., Smith A. D. Membranes of the adrenal medulla. Behaviour of insoluble proteins of chromaffin granules on gel electrophoresis. Biochem J. 1970 Jun;118(2):303–310. doi: 10.1042/bj1180303. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES